519 related articles for article (PubMed ID: 11770010)
1. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
2. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
7. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
Masubuchi N; Hakusui H; Okazaki O
Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
[TBL] [Abstract][Full Text] [Related]
8. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
9. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Parente F; Sainaghi M; Sangaletti O; Imbesi V; Maconi G; Anderloni A; Bianchi Porro G
Aliment Pharmacol Ther; 2002 Mar; 16(3):553-7. PubMed ID: 11876710
[TBL] [Abstract][Full Text] [Related]
10. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
11. The interaction of proton pump inhibitors with cytochromes P450.
Tucker GT
Aliment Pharmacol Ther; 1994; 8 Suppl 1():33-8. PubMed ID: 8180292
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors.
Masubuchi N; Okazaki O
Chem Biol Interact; 1997 Nov; 107(1-2):63-74. PubMed ID: 9402950
[TBL] [Abstract][Full Text] [Related]
13. Drug interactions with proton pump inhibitors.
Unge P; Andersson T
Drug Saf; 1997 Mar; 16(3):171-9. PubMed ID: 9098655
[TBL] [Abstract][Full Text] [Related]
14. The basis of differentiation of PPIs.
Sachs G; Shin JM
Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
[TBL] [Abstract][Full Text] [Related]
15. Pantoprazole and cyclosporine or tacrolimus.
Schwrer H; Lorf T; Ringe B; Ramadori G
Aliment Pharmacol Ther; 2001 Apr; 15(4):561-2. PubMed ID: 11284790
[No Abstract] [Full Text] [Related]
16. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
17. Safety of proton pump inhibitors--an overview.
Arnold R
Aliment Pharmacol Ther; 1994; 8 Suppl 1():65-70. PubMed ID: 8180297
[TBL] [Abstract][Full Text] [Related]
18. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
19. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
20. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Labenz J; Petersen KU; Rösch W; Koelz HR
Aliment Pharmacol Ther; 2003 Apr; 17(8):1015-9. PubMed ID: 12694083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
